SPY334.19+5.46 1.66%
DIA275.90+4.20 1.55%
IXIC11,117.53+203.96 1.87%

Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $161

Raymond James analyst Steven Seedhouse maintains Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform and lowers the price target from $170 to $161.

Benzinga · 01/08/2020 14:05

Raymond James analyst Steven Seedhouse maintains Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform and lowers the price target from $170 to $161.